Virus-like particles of the Foot-and-Mouth Disease Virus in Saccharomyces cerevisiae induce an immune response in a mouse model
Received: Aug 25, 2026; Revised: Oct 08, 2026; Accepted: Nov 07, 2026
Published Online: Nov 13, 2026
Abstract
Virus-like particle (VLP)–based vaccines represent an innovative strategy that mimics the structural properties of native viruses while lacking infectious genetic material, thereby combining safety with potent immunogenicity. This platform is increasingly recognized as one of the most promising approaches to induce effective, long-lasting protective immunity. Foot-and-mouth disease virus (FMDV), a member of the Picornaviridae family, is the causative agent of a highly contagious vesicular disease affecting cloven-hoofed animals and poses significant economic threats worldwide. Previously, we demonstrated that FMDV VLPs were successfully expressed, processed, and assembled into empty virus particles in Saccharomyces cerevisiae, maintaining the stability and assembly efficiency after 3 days at 30 °C. The results indicate that the yeast-based platform provides a favorable environment for proper folding and self-assembly of capsid proteins into structurally intact VLPs. Furthermore, a two-step purification protocol comprising size-exclusion chromatography followed by sucrose density gradient ultracentrifugation effectively removed host cell proteins and other contaminants, yielding highly purified and structurally homogeneous VLP preparations. In the current study, we further enhanced the stability and assembly efficiency of FMDV VLPs by optimizing culture conditions in the yeast expression system. Moreover, initial oral administration in a mouse model induced robust systemic and mucosal immune responses, with generated antibodies cross-reacting with bacterially expressed VP1, confirming the preservation of key antigenic determinants. The immunogenicity of purified VLPs was further evaluated by parenteral administration, and the induced antibodies recognized bacterially expressed VP1, indicating that the purified VLPs preserved antigenic determinants. Therefore, we have demonstrated the potent immunogenicity of these optimized VLPs in mice following both oral and parenteral administration, thereby inducing systemic and mucosal immune responses. We establish a promising yeast-based VLP platform for scalable FMDV vaccine development.
Metrics
QR Code of this Article:
Related Articles
Active dry yeast (Saccharomyces cerevisiae) improves rumen fatty acid profile by regulating rumen bacteria in finishing bulls
J Anim Sci Technol 2026;68(5):1382-1399.
Investigation of the impact of multi-strain probiotics containing
J Anim Sci Technol 2024;66(5):876-890.
Effect of
J Anim Sci Technol 2022;64(1):10-22.
Age-dependent immune response in pigs against foot-and-mouth disease virus
J Anim Sci Technol 2021;63(6):1376-1385.
Integrated effects of diet and probiotics on rumen microbiota and host physiology in ruminants
J Anim Sci Technol 2026;68(4):1002-1014.
